<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2687-0940</journal-id><journal-title-group><journal-title>Challenges in modern medicine</journal-title></journal-title-group><issn pub-type="epub">2687-0940</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2687-0940-2020-43-2-216-228</article-id><article-id pub-id-type="publisher-id">23</article-id><article-categories><subj-group subj-group-type="heading"><subject>CARDIOLOGY</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;RELATIONSHIP OF ALDOSTERONE AND FIBROSIS MARKERS IN THE PATHOGENESIS OF CHRONIC HEART FAILURE BY THE MIDDLE RANGE EJECTION FRACTION IN DIFFERENT AGE GROUPS&lt;/strong&gt;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;RELATIONSHIP OF ALDOSTERONE AND FIBROSIS MARKERS IN THE PATHOGENESIS OF CHRONIC HEART FAILURE BY THE MIDDLE RANGE EJECTION FRACTION IN DIFFERENT AGE GROUPS&lt;/strong&gt;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Gosteva</surname><given-names>Elena V.</given-names></name><name xml:lang="en"><surname>Gosteva</surname><given-names>Elena V.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Shepel</surname><given-names>Ruslan N.</given-names></name><name xml:lang="en"><surname>Shepel</surname><given-names>Ruslan N.</given-names></name></name-alternatives></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Osipova</surname><given-names>Olga A.</given-names></name><name xml:lang="en"><surname>Osipova</surname><given-names>Olga A.</given-names></name></name-alternatives></contrib></contrib-group><pub-date pub-type="epub"><year>2020</year></pub-date><volume>43</volume><issue>2</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/journal-medicine/2020/2/216-228.pdf" /><abstract xml:lang="ru"><p>Of particular interest is the study of the mechanisms of development of chronic heart failure (HF), especially with intermediate ejection fraction (HFmrEF) depending on age. Methods. The study involved 80 patients, age 55,7 &amp;plusmn; 9,3 years, HFmrEF, I&amp;ndash;II functional class (FC) HF. These patients are divided into: 1 group &amp;ndash; middle age (MA) &amp;ndash; 50.2 &amp;plusmn; 4.1 years (n = 40 people); 2 group-elderly (E) 60.4 &amp;plusmn; 3.8 years (n = 40 people). Results. In patients with MA, the level of aldosterone (AL) was 23 % higher than in KG (p &amp;lt; 0.01), in patients with E &amp;ndash; 204.3 &amp;plusmn; 32.6 PG/ml, which is higher than in KG by 33 % (p &amp;lt; 0.01) and than in MA by 14 % (p &amp;lt; 0.05). We have established a high correlation between the AL level and the HF FC r = 0.7819, (p &amp;lt; 0.001). Levels of TIMP-1 collagen balance markers in the group of patients with HFmrEF MA were higher than HFmrEF E (by 26 %, p &amp;lt; 0.01). Levels of MMP-1 in the group of E patients were 22 % higher (p &amp;lt; 0.01) than in MA patients. MMP-9 levels in the E group were significantly higher by 16 % (p &amp;lt; 0.01) than in the MA group. We performed a correlation analysis of the relationship between MMP-9 and TIMP-1, and found a moderate correlation (r = 0.65) in patients with E with HFmrEF. Conclusion: The severity of HF and age, increase the activation of the aldosterone system. Indicators AL HFmrEF higher in patients of advanced age. Elderly patients have degradation of the extracellular matrix, which is confirmed by an increase in MMP-1, MMP-9. The increase in blood TIMP-1 reflects the role of fibroblast formation in the progression of HF symptoms. Levels of AL, MMP, and TIMP-1 can be useful markers for identifying patients at risk of progression of HFmrEF, including as components of a multi-marker approach.</p></abstract><trans-abstract xml:lang="en"><p>Of particular interest is the study of the mechanisms of development of chronic heart failure (HF), especially with intermediate ejection fraction (HFmrEF) depending on age. Methods. The study involved 80 patients, age 55,7 &amp;plusmn; 9,3 years, HFmrEF, I&amp;ndash;II functional class (FC) HF. These patients are divided into: 1 group &amp;ndash; middle age (MA) &amp;ndash; 50.2 &amp;plusmn; 4.1 years (n = 40 people); 2 group-elderly (E) 60.4 &amp;plusmn; 3.8 years (n = 40 people). Results. In patients with MA, the level of aldosterone (AL) was 23 % higher than in KG (p &amp;lt; 0.01), in patients with E &amp;ndash; 204.3 &amp;plusmn; 32.6 PG/ml, which is higher than in KG by 33 % (p &amp;lt; 0.01) and than in MA by 14 % (p &amp;lt; 0.05). We have established a high correlation between the AL level and the HF FC r = 0.7819, (p &amp;lt; 0.001). Levels of TIMP-1 collagen balance markers in the group of patients with HFmrEF MA were higher than HFmrEF E (by 26 %, p &amp;lt; 0.01). Levels of MMP-1 in the group of E patients were 22 % higher (p &amp;lt; 0.01) than in MA patients. MMP-9 levels in the E group were significantly higher by 16 % (p &amp;lt; 0.01) than in the MA group. We performed a correlation analysis of the relationship between MMP-9 and TIMP-1, and found a moderate correlation (r = 0.65) in patients with E with HFmrEF. Conclusion: The severity of HF and age, increase the activation of the aldosterone system. Indicators AL HFmrEF higher in patients of advanced age. Elderly patients have degradation of the extracellular matrix, which is confirmed by an increase in MMP-1, MMP-9. The increase in blood TIMP-1 reflects the role of fibroblast formation in the progression of HF symptoms. Levels of AL, MMP, and TIMP-1 can be useful markers for identifying patients at risk of progression of HFmrEF, including as components of a multi-marker approach.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>chronic heart failure middle range ejection fraction</kwd><kwd>aldosterone</kwd><kwd>fibrosis markers</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic heart failure middle range ejection fraction</kwd><kwd>aldosterone</kwd><kwd>fibrosis markers</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Vologdina I.V., Simanenkov V.I., Poroshina E.G., Min&amp;#39;ko B.A. 2016. Kachestvo zhizni i priverzhennost&amp;#39; terapii u pacientov pozhilogo i starcheskogo vozrasta s hronicheskoj serdechnoj nedostat-ochnost&amp;#39;ju, komorbidnymi kognitivnymi i affektivnymi narushenijami [Quality of life and adherence in patients with heart failure, cognitive and affective impairment]. Vestnik Severo-Zapadnogo gosudar-stvennogo medicinskogo universiteta im. I.I. Mechnikova, 1 (8): 45&amp;ndash;49.</mixed-citation></ref><ref id="B2"><mixed-citation>Drapkina O.M., Drapkina Ju.S. 2012. Fibroz i aktivnost&amp;#39; renin-angiotenzin-al&amp;#39;dosteronovoj sis-temy [Fibrosis and renin-angiotensin-aldosterone system activity]. Realii i perspektivy. Arterial&amp;#39;naja gi-pertenzija, 18 (5): 449&amp;ndash;458.</mixed-citation></ref><ref id="B3"><mixed-citation>Klinicheskie rekomendacii. Hronicheskaja serdechnaja nedostatochnost&amp;#39; (HSN). 2016 [Clini-cal guidelines. Chronic heart failure (CHF)]. Obshhestvo specialistov po serdechnoj nedostatochnosti i Rossijskoe kardiologicheskoe obshhestvo. 92 s.</mixed-citation></ref><ref id="B4"><mixed-citation>Mareev V.Ju., Fomin I.V., Ageev F.T., Arutjunov G.P., Begrambekova Ju.L., Belenkov Ju.N., Vasjuk Ju.A., Galjavich A.S., Garganeeva A.A., Gendlin G.E., Giljarevskij S.R., Glezer M.G., Drap-kina O.M., Dupljakov D.V., Kobalava Zh.D., Koziolova N.A., Lopatin Ju.M., Mareev Ju.V., Moi-seev V.S., Nedoshivin A.O., Perepech N.B., Sitnikova M.Ju., Skibickij V.V., Tarlovskaja E.I., Chesniko-va A.I., Shljahto E.V. 2017. Klinicheskie rekomendacii. Hronicheskaja serdechnaja nedostatochnost&amp;#39; (HSN) [Clinical guidelines. Chronic heart failure (CHF)]. Serdechnaja Nedostatochnost&amp;#39;, 18 (3): 3&amp;ndash;40. DOI: 10.18087/rhfj.2017.1.2346.</mixed-citation></ref><ref id="B5"><mixed-citation>Mjasoedova E.I. 2016. Soderzhanie matriksnoj metalloproteinazy-1 i ee ingibitora u pacientov s ishemicheskoj kardiomiopatiej [Content of matrix metalloproteinase-1 and its inhibitor in patients with ischemic cardiomyopathy]. Vestnik novyh medicinskih tehnologij, 23 (4): 50&amp;ndash;53 DOI: 10.12737/23850.</mixed-citation></ref><ref id="B6"><mixed-citation>Osipova O.A. Nagibina A.I., Komisov A.A., Petrova G.D., Shehovcova L.V., Vlasenko M.A., Vlasenko O.A. 2016. Patomorfologicheskie mehanizmy reguljacii obrazovanija miokardial&amp;#39;nogo fibroza u bol&amp;#39;nyh hronicheskoj serdechnoj nedostatochnost&amp;#39;ju na fone ishemicheskoj bolezni serdca [Pathomorpho-logical mechanisms of the regulation of the formation of myocardial fibrosis in patients with chronic heart failure against ischemic heart disease]. Zhurnal serdechnaja nedostatochnost&amp;#39;, 17 (5): 357&amp;ndash;364. DOI: 10.18087/RHFJ.2016.5.2137.</mixed-citation></ref><ref id="B7"><mixed-citation>Osipova O.A., Nikitina V.V., Shehovcova L.V., Nagibina A.I., Vlasenko M.A. 2015. Nejrogumoral&amp;#39;nye moduljatory v lechenii bol&amp;#39;nyh s hronicheskoj serdechnoj nedostatochnost&amp;#39;ju [Neuro-humoral modulators in the treatment of patients with chronic heart failure]. Fundamental&amp;#39;nye issledovani-ja. 1 (8): 1655&amp;ndash;1658.</mixed-citation></ref><ref id="B8"><mixed-citation>Popov M.A., Shumakov D.V., Zybin D.I., Gurevich L.E., Ashevskaja V.E., Babokin V.E., Pronina V.P. 2019. Fenomen roli kollagena IV tipa i matriksnoj metalloproteinazy-9 tipa v remodeliro-vanii miokarda levogo zheludochka pri ishemicheskoj bolezni serdca [Role of type IV collagen and ma-trix metalloproteinase-9 in remodeling of the left ventricular in coronary artery disease]. Rossijskij kardi-ologicheskij zhurnal, 24 (8): 83&amp;ndash;87. DOI: 10.15829/1560-4071-2019-8-83-87.</mixed-citation></ref><ref id="B9"><mixed-citation>Reznik E.V., Nikitin I.G. 2019. Kardiorenal&amp;#39;nyj sindrom u bol&amp;#39;nyh s serdechnoj nedostato-chnost&amp;#39;ju kak jetap kardiorenal&amp;#39;nogo kontinuuma (chast&amp;#39; I): opredelenie, klassifikacija, patogenez, diag-nostika, jepidemiologija (obzor literatury) [Cardiorenal syndrome in patients with chronic heart failure as&amp;nbsp;a stage of the cardiorenal continuum (part I): Definition, classification, pathogenesis, diagnosis, epidemi-ology]. Arhiv&amp;quot; vnutrennej mediciny, 9 (1): 5&amp;ndash;22. DOI: 10.20514/2226-6704-2019-9-1-5-22.</mixed-citation></ref><ref id="B10"><mixed-citation>Burke R.M., Lighthouse J.K., Mickelsen D.M., Small E.M. 2019. Sacubitril/Valsartan De-creases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fi-broblasts. Circ. Heart Fail., 12 (4): e005565. DOI: 10.1161/CIRCHEARTFAILURE.118.005565.</mixed-citation></ref><ref id="B11"><mixed-citation>Cleland J.G.F., Lyon A.R., Mcdonahh T., McMurray J.J.V. 2020. The year in cardiology: the year in cardiology 2019, European Heart Journal, 41 (12): 1232&amp;ndash;1248, https://doi.org/10.1093/eurheartj/ehz949.</mixed-citation></ref><ref id="B12"><mixed-citation>Ferreira J.M., Ferreira S.M., Ferreira M.J., Falc&amp;atilde;o-Pires I. 2017. Circulating Biomarkers of Collagen Metabolism and Prognosis of Heart Failure with Reduced or Mid-Range Ejection Fraction. Curr. Pharm. Des., 23 (22): 3217&amp;ndash;3223. DOI: 10.2174/1381612823666170317124125.</mixed-citation></ref><ref id="B13"><mixed-citation>Horn M.A, Trafford A.W. 2016. Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling. Journal of Molecular and Cellular Cardiology 93, 175&amp;ndash;185. DOI: 10.1016 / j. yjmcc.2015.11.005.</mixed-citation></ref><ref id="B14"><mixed-citation>Kunkel G.H., Kunkel C.J., Ozuna H., Miralda I., Tyagi S.C. 2019. TFAM overexpression re-duces pathological cardiac remodeling. Molecular and cellular biochemistry, 454 (1&amp;ndash;2), 139&amp;ndash;152. https://doi.org/10.1007/s11010-018-3459-9.</mixed-citation></ref><ref id="B15"><mixed-citation>1Morishita T., Uzui H., Mitsuke Ya., Amaya N., Kaseno K., Ishida K. 2017. Association be-tween matrix metalloproteinase-9 and worsening heart failure events in patients with chronic heart failure. ESC Heart Failure; 4: 321&amp;ndash;330. DOI: 10.1002/ehf2.12137.</mixed-citation></ref><ref id="B16"><mixed-citation>M&amp;uuml;nzel T., Gori T., Keaney J.F.Jr., Maack C., Daiber A. 2015. Pathophysiological role of oxi-dative stress in systolic and diastolic heart failure and its therapeutic implications. European heart journal, 36 (38): 2555&amp;ndash;2564. https://doi.org/10.1093/eurheartj/ehv305.</mixed-citation></ref><ref id="B17"><mixed-citation>Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J., Falk V., Gonz&amp;aacute;-lez-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M., Ruilope L.M., Ruschitzka F., Rutten F.H. van der MPAFMDR. 2016. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 37: 2129&amp;ndash;200. DOI: 10.1002/ejhf.592.</mixed-citation></ref><ref id="B18"><mixed-citation>Pugliese N.R., Masi S., Taddei, S. 2020. The renin-angiotensin-aldosterone system: a cross-road from arterial hypertension to heart failure. Heart. Fail. Rev. 25, 31&amp;ndash;42. doi.org/10.1007/s10741-019-09855-5.</mixed-citation></ref><ref id="B19"><mixed-citation>Radosinska J., Barancik M., Vrbjar N. 2017. Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Med., 59 (3): 241&amp;ndash;253. DOI: 10.23736/S0031-0808.17.03321-3.</mixed-citation></ref><ref id="B20"><mixed-citation>Sanchis L. 2015. Prognosis of new-onset heart failure outpatients and collagen biomarkers. Eur. J. Clin. Invest., 45: 842&amp;ndash;849.</mixed-citation></ref><ref id="B21"><mixed-citation>Simmonds S., Cuijpers I., Heymans S., Jones E. 2020. Cellular and Molecular Differences be-tween HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. Cells, 9 (1): 242. https://doi.org/10.3390/cells9010242.</mixed-citation></ref><ref id="B22"><mixed-citation>Toba H., Lindsey M.L. 2019. Extracellular matrix roles in cardiorenal fibrosis: Potential ther-apeutic targets for CVD and CKD in the elderly. Pharmacol. Ther., 193: 99&amp;ndash;120. doi:10.1016/j.pharmthera.2018.08.014.</mixed-citation></ref></ref-list></back></article>